Talecris stock slips as demand for blood-plasma products wane

12/1/2009 | News & Observer (Raleigh, N.C.), The

Shares of Talecris, a maker of blood plasma-derived treatments for various immune disorders, dropped Monday by almost 20% since reaching a high in early November, amid concerns that the company won't be able to sustain its rising profit into the coming year. Analysts say the economic downturn could create an oversupply in blood-plasma products as more people donate.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC